AmpliPhi Biosciences Announces Pricing of $6.6 Million Underwritten Public Offering

/in

CATEGORY: Featured Friday, October 12, 2018 6:00 am EDT SAN DIEGO EmailPDFPrintRSS PUBLIC COMPANY INFORMATION: NYSEAM: APHB SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSE AMERICAN: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for patients with serious and life-threatening antibiotic-resistant bacterial infections, today announced the pricing of an underwritten public offering of 16,537,500 […]

Read more

AmpliPhi Biosciences Announces Presentation of Positive Clinical Data From its Expanded Access Program for Serious S. aureus Infections at IDWeek 2018 Conference

/in

 13 patients with serious and life-threatening S. aureus infections were treated with AB-SA01 at the Westmead Hospital in Sydney under AmpliPhi’s expanded access program  Patients suffered from severe S. aureus bacteremia and sepsis, including infective endocarditis and prosthetic valve endocarditis  83% (10 out of 12) patients in the modified intent-to-treat (mITT) population achieved treatment success […]

Read more

Adherium Announces Participation in SmartAirLA Effort to Combat Asthma in Los Angeles with Support from Blue Shield of California Foundation

/in

03 Oct 2018 Adherium (ASX:ADR), a leading digital health platform for medication adherence today announced its participation in the launch of the SmartAirLA program to empower communities to reduce the effects and prevalence of asthma in Los Angeles through Internet of Things technology. Using Adherium’s Hailie™ solution, SmartAirLA will help patients with asthma and COPD […]

Read more